loading page

Monoclonal antibody and blood plasma ABO blood group based therapy against COVID-19
  • Kalayu Shimuye,
  • Jianda Hu,
  • Minhui Lin
Kalayu Shimuye
Fujian Medical University
Author Profile
Jianda Hu
Fujian Medical University
Author Profile
Minhui Lin
Fujian Medical University
Author Profile

Abstract

In new decade new coronavirus emerged. By April 2020, there is no accepted antiviral drug or antibody against COVID-19. COVID-19 (SARS-CoV-2) has nucleic acid sequence similarity 96% with bat coronavirus, 79.6% SARS-CoV-1. SARS-CoV-2 and SARS-CoV-1have common human host-cell ACE2 receptor. This similarity helps for effective vaccine and antibody development. At Wuhan, China, convalescent plasma therapy achieved 70% recovery results. ABO blood group susceptibility study revealed O blood group were very low risk whereas A were at high risk against COVID-19. ABO natural antibodies have positive effect to slowdown COVID-19 in less hygienic environment (less developed region). Isolation of specific antibody from EBV transformed B-lymphocyte recovered patients is encouraged. Urgent production of potent neutralizing antibody and vaccine is required and we identified sensitive immunogenic amino acid segment (318-510) in S1-protein domain that contains important and essential amino acids including cysteine, glutamic acid and aspartic acid, which associated with ACE2 expression.